Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR4 | P31391 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.31 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16057149 | 0.80 | CACNA1G (0.41) | — | |
| SCHEMBL3386758 | 0.80 | HRH3 (0.59) | HRH3 | |
| SCHEMBL12407048 | 0.72 | CACNA1G (0.37) | HRH3 | |
| SCHEMBL17827868 | 0.70 | SSTR4 (0.36) | SSTR4MLYCDHDAC3HDAC1HDAC2 | |
| SCHEMBL3558466 | 0.69 | HCAR2 (0.45) | HRH3HCAR2 | |
| SCHEMBL13984783 | 0.69 | HDAC1 (0.49) | MLYCDHDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL1732802 | 0.69 | USP30 (0.30) | — | |
| SCHEMBL17873711 | 0.69 | SSTR4 (0.36) | SSTR4HDAC3HDAC1HDAC2NCOR2 | |
| SCHEMBL3586130 | 0.69 | KDM4A (0.40) | — | |
| SCHEMBL25039089 | 0.69 | ALOX5AP (0.35) | HRH3HCAR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1771432-B1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS AS HISTAMINE H3 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-12-08 | — | — | EP | disclosed |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | CARRUTHERS NICHOLAS I | 2008-12-25 | — | — | US | disclosed |
| US-7429659-B2 | Furan compounds as histamine H3 modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-09-30 | — | — | US | disclosed |
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | JANSSEN PHARMACEUTICAL, N.V. (BE) | 2005-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222129-A1 | Non-imidazole heterocyclic compounds | HRH3, HRH4, HRH2 | SSTR4 1423/4885HRH3 1/4885MLYCD 3835/4885 |
| US-20080317671-A1 | NON-IMIDAZOLE HETEROCYCLIC COMPOUNDS | HRH3, HRH4, HRH2 | SSTR4 1423/4885HRH3 1/4885MLYCD 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.